The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.
RSS Feed for InvestorBrandNetwork (IBN)December 4, 2025 — The start of this week saw the price of gold surge to a new high, bolstered by a weakening dollar and increasing expectations of rate cuts by the Fed. The precious metal’s price hit $4,241.
December 4, 2025 — Disseminated on behalf of ShelfieTech Ltd. (CSE: SHLF) (OTCQB: SHLFF) and may include paid advertising.
December 4, 2025 — This article has been disseminated on behalf of Canamera Energy Metals Corp. and may include paid advertising.
December 4, 2025 — eCommerce has changed quickly, and 2025 looks nothing like the early days when brands could pack orders from a small room and ship them out with little stress. Today, online shopping has higher demand, faster delivery standards, and far more competition.
December 4, 2025 — Bitcoin and crypto-related shares extended their nearly two-month slide on Dec. 1, mirroring a broader retreat in tech shares that many investors argue have climbed too far, too fast.
December 4, 2025 — Massimo Group (NASDAQ: MAMO) has established Massimo AI Technology Inc. , a wholly owned subsidiary created to advance the company into industrial and service robotics while supporting its long-term technology roadmap.
December 4, 2025 — BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U. S.
December 4, 2025 — Norway saw almost all new car registrations go electric in November. The country recorded 19,427 battery-only vehicles out of 19,899 newly registered passenger cars, pushing the EV share to 97.
December 3, 2025 — A surge in hemp-derived THC products that reshaped convenience store shelves and fueled a fast-growing market appears to be heading toward a sharp slowdown. Tucked inside the bill that brought an end to the recent federal shutdown is a clause that would outlaw hemp-derived THC products nationwide.
December 3, 2025 — Gloo (NASDAQ: GLOO) , a technology platform serving the faith and flourishing ecosystem, priced its initial public offering of 9,100,000 shares of Class A common stock at $8 per share and granted underwriters a 30-day option to purchase up to 1,365,000 additional shares. Trading is expected to begin on the Nasdaq Global Select Market under the symbol GLOO, with the offering slated to close Nov.
December 3, 2025 — Safe Pro Group (NASDAQ: SPAI), a mission-driven provider of AI-powered defense and security solutions, is aligned with a major federal shift as the War Department moves to acquire roughly 300,000 low-cost drones under President Trump’s “Unleashing American Drone Dominance” initiative. The department’s new request for information outlines a $1 billion procurement program beginning in early 2026 that will fund four production “gauntlets,” starting with 12 vendors delivering 30,000 drones at $5,000 per unit and scaling toward 150,000 units at reduced costs.
December 3, 2025 — Decent Holding (NASDAQ: DXST), an established wastewater treatment services provider in China, closed its $8 million registered offering consisting of 13,333,333 Class A ordinary shares at $0. 60 per share and warrants to purchase 26,666,666 additional shares at 110 percent of the offering price with a 120-day term.
December 3, 2025 — Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic and tissue-distribution data showing that Sapu003, its intravenous Deciparticle (TM) formulation of everolimus, dramatically reduces gastrointestinal drug accumulation compared with oral everolimus. Oral dosing drives extreme gut exposure—up to 2,448× plasma levels in the stomach—while IV Sapu003 limits GI tissue levels to just 36–48× plasma, representing reductions of up to 67-fold.
December 3, 2025 — A2Z Cust2Mate Solutions specializes in creating, commercializing smart-cart solutions for grocery stores, supermarkets and other retail formats. The company’s mission is to “unlock the full potential of every in-store shopping journey, through digitalization and personalization.
December 3, 2025 — Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints for safety and tolerability and established a clear recommended Phase 2 dose.
December 3, 2025 — The energy company plans to begin servicing its own wells and market rigs and service equipment to third-party operators. CEO Michael McLaren says the operational restart of the Oil and Gas (“O&G”) service division will reduce maintenance and workover costs.
December 3, 2025 — A2Z Cust2Mate Solutions (NASDAQ: AZ), a global smart retail technology company, said it entered an agreement with a premium grocery retailer operating more than 50 stores in Central America to deploy the A2Z Cust2mate smart cart platform. Initial rollout is planned for early 2026 in two flagship locations, with the shared goal of expanding to a full chain-wide deployment following successful implementation.
December 3, 2025 — Micropolis AI Robotics (NYSE American: MCRP), a UAE-based developer of autonomous mobile robots and AI-driven security solutions, said it signed a non-binding Letter of Intent with QSS Robotics to establish a strategic collaboration for the distribution, localization, and deployment of Micropolis technologies across Saudi Arabia. The LOI outlines plans for commercial representation, joint engagement with government and private-sector customers, and integration and after-sales support under Micropolis supervision, building on agreements between the companies dating to 2022.
December 3, 2025 — Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.
December 3, 2025 — Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare diseases affecting more than 30 million Americans and the urgent need for new therapies. The article spotlights Soligenix’s late-stage development of HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma, now in its final confirmatory study before worldwide marketing submissions, and places the Company’s efforts at the intersection of advancing treatment options and emerging national health policy initiatives.